KR20220054593A - 병용 치료를 위한 화합물 - Google Patents

병용 치료를 위한 화합물 Download PDF

Info

Publication number
KR20220054593A
KR20220054593A KR1020227005609A KR20227005609A KR20220054593A KR 20220054593 A KR20220054593 A KR 20220054593A KR 1020227005609 A KR1020227005609 A KR 1020227005609A KR 20227005609 A KR20227005609 A KR 20227005609A KR 20220054593 A KR20220054593 A KR 20220054593A
Authority
KR
South Korea
Prior art keywords
compound
years
subject
treatment
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227005609A
Other languages
English (en)
Korean (ko)
Inventor
울프 시몬센
시몬 코메마-스테펜센
단 피터스
Original Assignee
이니시에이터 파마 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이니시에이터 파마 에이/에스 filed Critical 이니시에이터 파마 에이/에스
Publication of KR20220054593A publication Critical patent/KR20220054593A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
KR1020227005609A 2019-08-06 2020-08-06 병용 치료를 위한 화합물 Pending KR20220054593A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19190224.6 2019-08-06
EP19190224 2019-08-06
PCT/EP2020/072092 WO2021023805A1 (en) 2019-08-06 2020-08-06 Compound for combination treatment

Publications (1)

Publication Number Publication Date
KR20220054593A true KR20220054593A (ko) 2022-05-03

Family

ID=67551141

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227005609A Pending KR20220054593A (ko) 2019-08-06 2020-08-06 병용 치료를 위한 화합물

Country Status (16)

Country Link
US (1) US20220288052A1 (https=)
EP (2) EP4009942B1 (https=)
JP (1) JP7605825B2 (https=)
KR (1) KR20220054593A (https=)
CN (1) CN114430679A (https=)
AU (1) AU2020326244B2 (https=)
BR (1) BR112022002169A2 (https=)
CA (1) CA3146837A1 (https=)
DK (1) DK4009942T3 (https=)
ES (1) ES2962648T3 (https=)
FI (1) FI4009942T3 (https=)
IL (1) IL290319B2 (https=)
MX (1) MX2022000356A (https=)
PL (1) PL4009942T3 (https=)
WO (1) WO2021023805A1 (https=)
ZA (1) ZA202200723B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4646204A1 (en) * 2023-01-03 2025-11-12 Initiator Pharma A/S Compound for treatment of erectile dysfunction
WO2025051846A1 (en) 2023-09-05 2025-03-13 Initiator Pharma A/S Compound for treatment of female sexual dysfunction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04012693A (es) * 2002-06-20 2005-03-23 Lundbeck & Co As H Terapia de combinacion en donde se utiliza un inhibidor de recaptacion de serotonina.
RU2354377C2 (ru) * 2003-07-11 2009-05-10 Берингер Ингельхайм Ветмедика Гмбх Способ лечения или предупреждения заболеваний центральной нервной системы с использованием соединений, обладающих селективностью в отношении альфа-3-субъединицы бензодиазепинового рецептора
BRPI0515261A (pt) * 2004-09-30 2008-07-15 Neurosearch As composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo
WO2008074798A1 (en) * 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
BRPI0917802A2 (pt) * 2008-08-21 2016-03-01 Neurosearch As método para tratar um distúrbio de ansiedade, composição farmacêutica, uso do composto, uso de uma combinação, kit de partes, método para tratar, prevenir ou aliviar um distúrbio de ansiedade de um corpo de animal vivo, e, combinação
US20130040985A1 (en) 2010-01-29 2013-02-14 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Also Published As

Publication number Publication date
WO2021023805A1 (en) 2021-02-11
MX2022000356A (es) 2022-05-11
FI4009942T3 (fi) 2023-09-26
CN114430679A (zh) 2022-05-03
ES2962648T3 (es) 2024-03-20
BR112022002169A2 (pt) 2022-06-07
AU2020326244B2 (en) 2025-06-05
AU2020326244A1 (en) 2022-03-17
IL290319A (en) 2022-04-01
IL290319B2 (en) 2023-06-01
DK4009942T3 (da) 2023-10-23
EP4009942B1 (en) 2023-08-09
EP4009942A1 (en) 2022-06-15
CA3146837A1 (en) 2021-02-11
ZA202200723B (en) 2022-08-31
EP4241839A2 (en) 2023-09-13
JP7605825B2 (ja) 2024-12-24
US20220288052A1 (en) 2022-09-15
JP2022544463A (ja) 2022-10-19
PL4009942T3 (pl) 2024-04-08
EP4241839A3 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
Behr-Roussel et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis
ES2757922T3 (es) Agonistas y composiciones del receptor 5-HT2C y métodos de uso
US11608339B2 (en) 5-HT2C receptor agonists and compositions and methods of use
WO2021231646A1 (en) Combination treatment of liver disorders
PT1149579E (pt) Utilização de um agonista/antagonista de estrogénio para tratamento da disfunção sexual feminina
US20160256449A1 (en) H3 receptor antagonist for use in the treatment of alzheimer&#39;s disease
KR20220054593A (ko) 병용 치료를 위한 화합물
MXPA02007003A (es) Metodo para la ansiedad.
NZ567963A (en) Pharmaceutical combinations comprising testosterone in the treatment of female sexual dysfunction
KR100614504B1 (ko) 임상적 우울증 치료를 위한 디옥시페가닌의 용도
TW201605856A (zh) ５－ＨＴｃ受體促效劑
EP1655029A1 (en) Medicinal compositions
HK40099487A (en) Compound for combination treatment
Jori et al. Effect of piribedil and one of its metabolites on the concentration of homovanillic acid in the rat brain
BR112020017026A2 (pt) 3ss-(4-metoxibenziloxi)pregn-5-en-20-ona para uso no tratamento de transtornos relacionados a canabinoides
HK40071713A (en) Compound for combination treatment
HK40071713B (en) Compound for combination treatment
JP2025087929A (ja) うつ病および／またはうつ状態の治療および／または予防用医薬
WO2007004226A2 (en) Compositions and methods for treatment of male erectile dysfunction (ed)
HK1155063A (en) Treatment of post-traumatic stress disorder
JP2010222347A (ja) Ｐｄｅ５阻害剤及びカルニチンを含有する医薬組成物
HK1128226B (en) Pharmaceutical combinations comprising testosterone in the treatment of female sexual dysfunction

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902